"We are beginning with tuberculosis", the CEO added. The California-based biotech company Trianni Inc. which Wabl established a few years ago has ensured the necessary pre-requisites for this. “The main problem is the resistance against antibiotics, but there is an alternative, namely antibodies”, said the trained chemist and biologist, who teaches microbiology and immunology at the American university. Trianni created the platform enabling the antibodies to be identified. This means genetic mice developed for this purpose. In addition to various pharmaceutical companies, Austrianni is one of the licensees of the patented antibody platform and can continue researching on this basis. The mice mentioned above produce the humanized antibodies needed to fight tuberculosis and other diseases.
The business location decision of Austrianni was not only based on the roots of the company’s founder in Austria. „There are very generous funding possibilities here. This is one of the main reasons“, Wabl added. Up to 70 percent of the project costs can be contributed by the Austrian Research Promotion Agency FFG. Moreover, Austria “is making great efforts to expand its biotech sector”, Wabl concluded.